skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:6735378

Since thallium-201 imaging has been reported as a potential means of follow-up of patients with differentiated thyroid carcinoma (DTC) during ongoing thyroid suppression therapy, the authors evaluated the diagnostic sensitivity of this procedure in 31 patients known to have metastases or local recurrence. Among 51 tumor sites /sup 201/TI imaging had a detection rate of 45% whereas 84% was noted for imaging with /sup 131/I administered in therapeutic doses. Thus, even though the effectiveness of the two radionuclides is not strictly comparable due to the difference in the administered doses, Thallium imaging cannot be recommended as the only modality for the follow-up of patients with DTC. Six of the eight tumor sites negative with /sup 131/I were positive with /sup 201/TI (especially metastatic cervico-mediastinal lymph nodes). So /sup 201/TI imaging may particularly be helpful in localizing metastases or recurrences in patients with a negative /sup 131/I scan and abnormal levels of serum thyroglobulin.

Research Organization:
Hopital Universitaire Pellegrin, Bordeaux (France)
OSTI ID:
6735378
Journal Information:
J. Nucl. Med.; (United States), Vol. 29:9
Country of Publication:
United States
Language:
English